TSC2 regulates VEGF through mTOR-dependent and -independent pathways. - Wikidata - awgldk - TriplyDB

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

http://www.wikidata.org/entity/Q44574474

about

PI3K/AKT/mTOR Pathway in Angiogenesis Systematic Analysis Reveals Elongation Factor 2 and α-Enolase as Novel Interaction Partners of AKT2 Signaling by target of rapamycin proteins in cell growth control Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Metabolism of kidney cancer: from the lab to clinical practice Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth The Lin28/let-7 axis regulates glucose metabolism Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis The tuberous sclerosis complex State of the science: an update on renal cell carcinoma mTOR signaling in growth control and disease MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects Hypoxic control of metastasis A review of therapies for diabetic macular oedema and rationale for combination therapy The metabolic basis of kidney cancer The ever-expanding role of HIF in tumour and stromal biology Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress Activation of a metabolic gene regulatory network downstream of mTOR complex 1 Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics The LKB1-AMPK pathway: metabolism and growth control in tumour suppression Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Normalization of the vasculature for treatment of cancer and other diseases.Role of the ubiquitin proteasome system in renal cell carcinoma.Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birt Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors.Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration: implications for treatment of port-wine stain birthmarks Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors Trimming of mammalian transcriptional networks using network component analysis.Lymphangioleiomyomatosis and TSC2-/- cells

P2860

Q21129332-14835CEF-E749-4EFA-B325-9A404A3EC0CB Q24297375-BB5A53C7-2441-48CE-916E-305E73D07B77 Q24522447-3BABAF4D-ADB9-4A89-A570-9CF34127C536 Q24548951-484D5100-812D-4146-B2A9-7B86AA2FFBA1 Q24559347-93374B62-2B87-422D-8168-81BCBAA85ECC Q24600512-88CF6882-0772-4D08-9640-6E47A9D62248 Q24603549-5C653552-E95E-4A97-AE14-AFFE6BE60D51 Q24620363-30E597FE-57C0-4A62-ABD0-F70DE0FF7F93 Q24620427-D53B212C-3174-4CE2-9C7B-6B4764033E79 Q24628011-C25522F9-A3DE-4678-8A31-2CB6FDBF4469 Q24630685-974CD488-5518-423F-A91E-F36E5C154BDF Q24634174-57DECAB8-DCF2-4D6F-A325-0D0E68347043 Q25255189-02120E38-7047-45E0-B19C-B73B8B41CDEB Q25255621-75B43647-3645-4671-92B8-D6F1C770EE74 Q26749011-A563948A-8161-4DBE-895A-9014B94F747E Q26749159-AD97F05A-325C-4640-8C2F-D9CB1DFAC04D Q27008325-2B8FD1DA-7D07-4388-80C9-3A290807AE77 Q27023273-1C8958A0-9A2F-4B77-8EEC-234B1AA7AAFD Q28079015-D74B8F4B-A5A7-48C4-945F-71422B5FA454 Q28262376-10168030-2D62-4061-AC2F-74CD83DE82F1 Q28393897-B8CEBAA1-E804-421F-830D-DA80D3EB75BE Q28728348-F9A17460-6CA8-4E21-B8CD-20A6CD91A97A Q28729157-DAFE0409-39D2-495A-AEF9-3C040EC31E6A Q29614493-CD2EF9C0-9C19-457C-B68D-1EBAC6D8048C Q29615179-9B72DB8B-43E2-4CC1-BE4A-A580934557F7 Q29615944-6730DAA0-42B2-41C7-8356-1C4F1CA9D041 Q29617506-0BC6F90A-8692-4975-96C7-0EC11869A866 Q30412106-8B97A667-D6BB-4E5B-BB59-97B0E2A26887 Q30471456-758C3905-3E26-447B-9B69-97E7F25C43EE Q33307879-447CF26A-C3FD-4681-892D-1B5412A115A9 Q33316503-64A8A739-43EE-4C50-B1AF-9DB2A46FF655 Q33317794-C763AF94-F350-429D-A48F-46844A0FE882 Q33430534-C863774F-0F86-44E2-BED8-88D86AAC2070 Q33480974-A5B58734-BEF1-437A-82B7-A3D7851071CE Q33498333-31F1E1A4-9DED-4636-B4DE-C2D83C2C6798 Q33581062-DA9E2CBD-1E60-40AB-A088-F6CBF3928E6E Q33623036-B07587A7-1BE5-42A1-943B-05BCC868E870 Q33711691-F2CF7F25-A0D4-4BD1-B4B3-B6760A25D148 Q33717504-3DEBF992-E4A1-4B1B-B7A5-F1EE878C0D5A Q33904951-48C39154-9D90-4761-89EA-F13C38122B97

P2860

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

http://www.wikidata.org/entity/Q44574474

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@en

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@nl

type

label

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@en

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@nl

prefLabel

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@en

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@nl

P1433

Q44574474-1846A2BD-5AFA-409E-B297-BB662A131CD1

P1476

Q44574474-3EC26891-4D8B-48B1-BBC0-31E5401E3FC4

P2093

Q44574474-1E41E718-2C01-41E0-90E5-76D68134D3FB

Q44574474-2256EAEA-43F2-46CB-880D-BFCA5F4E46D4

Q44574474-968C4279-1814-465D-A87C-F924754CA959

Q44574474-FFCB9EA4-0761-4978-9805-72E22462C6C7

P304

Q44574474-876179BB-BB9E-48D5-AA8B-7AD79F961741

P31

Q44574474-A158CE68-6374-41BD-BA90-B9744CF43C9F

P356

Q44574474-B14EA04E-23A2-4A6F-A392-D857F9F38078

P433

Q44574474-6DA4EEF8-887E-48C3-BE86-06FC824C6901

P478

Q44574474-994DF9D5-EF5C-4A11-98F2-A35B05F5AB6E

P50

Q44574474-4E172CCB-54A5-47C2-9DFA-65851A8B3C6B

P577

Q44574474-3AAC7272-5E45-420A-B79E-32B1DE4F192E

P5875

Q44574474-7FA80B32-EFAB-4B11-B6BA-2E9D14EE3372

P698

Q44574474-AF43FD65-B555-4C23-A48B-EB55CCC1A5B0

P356

S1535-6108(03)00187-9

P1433

P1476

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

@en

P2093

Archana Reddy

http://www.w3.org/2001/XMLSchema#string

Francisca Vazquez

http://www.w3.org/2001/XMLSchema#string

James B Brugarolas

http://www.w3.org/2001/XMLSchema#string

William R Sellers

http://www.w3.org/2001/XMLSchema#string

P304

147-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1535-6108(03)00187-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

William G. Kaelin

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10581851

http://www.w3.org/2001/XMLSchema#string

P698

12957289

http://www.w3.org/2001/XMLSchema#string